SCHEMBL16184094

SCHEMBL16184094

CCOc1ccc2nc(-c3cccnc3)nc(Nc3ccc(Cl)cn3)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 7/20 0.52
▸ ABCG2 Q9UNQ0 6/20 0.52
▸ CYP19A1 P11511 1/20 0.46
▸ CYP11B1 P15538 1/20 0.46
▸ CYP11B2 P19099 1/20 0.46
▸ ABCB1 P08183 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14473963 0.90 ABCG2 (0.61) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL16183340 0.90 PDE5A (0.52) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL16183347 0.90 PDE5A (0.52) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL16184104 0.89 ABCG2 (0.52) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL14726069 0.87 ABCG2 (0.58) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL14474371 0.85 PDE5A (0.59) PDE5AABCG2ABCB1KDM4EMAPT
SCHEMBL16183358 0.85 ABCG2 (0.50) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL16183359 0.85 ABCG2 (0.56) PDE5AABCG2ABCB1KDM4EMAPT
SCHEMBL16184095 0.85 ABCG2 (0.52) PDE5AABCG2CYP19A1CYP11B1CYP11B2
SCHEMBL16183357 0.83 ABCG2 (0.50) PDE5AABCG2CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB PDE5A 704/4885ABCG2 1597/4885CYP19A1 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback